FIT for Symptomatic Testing

FIT for Symptomatic Testing

NICE DG30 recommends Faecal Immunochemical Tests for adoption in primary care to triage patients and guide referral for suspected colorectal cancer in people without rectal bleeding who have unexplained symptoms but do not meet the criteria for a suspected cancer pathway referral outlined in NICE guideline NG12.


Read More

NICE Diagnostics Guidance DG30

NICE Diagnostics Guidance DG30

NICE guidance DG30 recommends “Quantitative faecal immunochemical tests (FIT) to guide referral for colorectal cancer in primary care”
NICE reviewed 10 publications on FIT in the symptomatic population and concluded that a cut off of 10 µg of Hb/ g faeces had a high negative predictive value (NPV) for cancer plus other serious bowel diseases.


Read More

FIT for Bowel Cancer Screening

FIT for Bowel Cancer Screening

The National Bowel Cancer Screening Programmes reduce the risk of dying from bowel cancer by detecting disease before symptoms appear, when it is easier to treat and there is a better chance of survival.
FIT is now being adopted as the standard test method across the screening programmes.


Read More

Automated FIT: Easy as 1-2-3

Automated FIT: Easy as 1-2-3

The NICE DG30 evidence review, reported HM-JACKarc with 100% sensitivity, 76.6% specificity, 6.1% positive predictive value and 100% negative predictive value for colorectal cancer.
[FIT] assays were also cost effective when compared with no triage, with the HM-JACKarc dominating (that is, it was more effective and less expensive)


Read More

What is the FIT Test?

The faecal immunochemical test (FIT Test) is now an established bowel cancer test. This diagnostic assay identifies the presence of hidden blood in the stool, known as faecal occult blood (FOB), which can be an early sign of colorectal cancer. FIT uses antibodies specific to human haemoglobin so is more accurate and sensitive, provides a quantitative measurement and gives fewer false positive results than other tests.

Read More

Benefits of FIT for Screening

For the National Bowel Cancer Screening programmes the FIT Test is bringing many advantages. Easier sampling methods are more acceptable to people invited for screening, which promotes greater uptake. Non-subjective, automated processing of samples advances laboratory efficiencies, improving standardisation and quality control. FIT is more sensitive and can detect cancers more reliably and at an earlier stage.

Read More

Benefits of FIT for Symptomatic Testing

NICE Guidance DG30 now recommends “Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care”. NICE concludes that a cut off of 10 μg of Hb/ g faeces in a FIT Test has a high negative predictive value for colorectal cancer and other serious bowel diseases. FIT should be used to triage for referral to secondary care, people whose symptoms suggest colorectal cancer, but in whom a definitive diagnosis of cancer is unlikely.

Read More

Recent FIT Resources

Faecal Immunochemical Test (FIT) Sample Collection

The HM-JACKarc FIT system employs an innovative sample collection device that

‘FIT to Practice?’ Workshop – ACB Focus – June 2018

This Industry Sponsored Workshop entitled ‘FIT to Practice?’ was given by

Q&A Session ‘FIT to Practice?’ – ACB Focus – June 2018

Catch the interactive audience discussions from the workshop held at ACB

Hull-Clinical-Biochemistry-Team
Feasibility of FIT – the Hull Experience

Setting up a FIT Feasibility Study and considerations for ISO 15189

FIT Solutions


  • HM-JACKarc Automated FITHM-JACKarc Automated FIT Test
  • FIT-Solutions-Innovative-Sampling-DeviceInnovative FIT Sample Collection Device
  • Sensitive Latex TurbidimetrySensitive Latex Turbidimetry
  • Customised Instructions for UseCustomised FIT Test Instructions for Use
  • FIT Logistic SolutionsComplete Patient Packs